An organoid biobank for childhood kidney cancers that captures disease and tissue heterogeneity.
Adolescent
Biological Specimen Banks
Carcinoma, Renal Cell
/ drug therapy
Cell Culture Techniques
/ methods
Child
Child, Preschool
DNA Methylation
Drug Screening Assays, Antitumor
/ methods
Female
Gene Expression Regulation, Neoplastic
Genetic Heterogeneity
Genotyping Techniques
Humans
Infant
Kidney
/ pathology
Kidney Neoplasms
/ drug therapy
Male
Nephroma, Mesoblastic
/ drug therapy
Netherlands
Organoids
/ pathology
Precision Medicine
/ methods
RNA-Seq
Rhabdoid Tumor
/ drug therapy
Single-Cell Analysis
Transfection
Tumor Cells, Cultured
Whole Genome Sequencing
Wilms Tumor
/ drug therapy
Young Adult
Journal
Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555
Informations de publication
Date de publication:
11 03 2020
11 03 2020
Historique:
received:
10
01
2019
accepted:
21
02
2020
entrez:
13
3
2020
pubmed:
13
3
2020
medline:
14
7
2020
Statut:
epublish
Résumé
Kidney tumours are among the most common solid tumours in children, comprising distinct subtypes differing in many aspects, including cell-of-origin, genetics, and pathology. Pre-clinical cell models capturing the disease heterogeneity are currently lacking. Here, we describe the first paediatric cancer organoid biobank. It contains tumour and matching normal kidney organoids from over 50 children with different subtypes of kidney cancer, including Wilms tumours, malignant rhabdoid tumours, renal cell carcinomas, and congenital mesoblastic nephromas. Paediatric kidney tumour organoids retain key properties of native tumours, useful for revealing patient-specific drug sensitivities. Using single cell RNA-sequencing and high resolution 3D imaging, we further demonstrate that organoid cultures derived from Wilms tumours consist of multiple different cell types, including epithelial, stromal and blastemal-like cells. Our organoid biobank captures the heterogeneity of paediatric kidney tumours, providing a representative collection of well-characterised models for basic cancer research, drug-screening and personalised medicine.
Identifiants
pubmed: 32161258
doi: 10.1038/s41467-020-15155-6
pii: 10.1038/s41467-020-15155-6
pmc: PMC7066173
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Video-Audio Media
Langues
eng
Sous-ensembles de citation
IM
Pagination
1310Références
Pui, C. H., Gajjar, A. J., Kane, J. R., Qaddoumi, I. A. & Pappo, A. S. Challenging issues in pediatric oncology. Nat. Rev. Clin. Oncol. 8, 540–549 (2011).
pubmed: 21709698
pmcid: 3234106
doi: 10.1038/nrclinonc.2011.95
Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2016. CA Cancer J. Clin. 66, 7–30 (2016).
pubmed: 26742998
doi: 10.3322/caac.21332
Breslow, N., Olshan, A., Beckwith, J. B. & Green, D. M. Epidemiology of Wilms tumor. Med Pediatr. Oncol. 21, 172–181 (1993).
pubmed: 7680412
doi: 10.1002/mpo.2950210305
Gooskens, S. L. et al. Congenital mesoblastic nephroma 50 years after its recognition: a narrative review. Pediatr. Blood Cancer 64, e26437 (2017).
doi: 10.1002/pbc.26437
van den Heuvel-Eibrink, M. M. et al. Position paper: rationale for the treatment of Wilms tumour in the UMBRELLA SIOP-RTSG 2016 protocol. Nat. Rev. Urol. 14, 743–752 (2017).
pubmed: 29089605
doi: 10.1038/nrurol.2017.163
pmcid: 29089605
Gooskens, S. L. et al. Position paper: Rationale for the treatment of children with CCSK in the UMBRELLA SIOP-RTSG 2016 protocol. Nat. Rev. Urol. 15, 309–319 (2018).
pubmed: 29485128
doi: 10.1038/nrurol.2018.14
pmcid: 29485128
Brok, J., Treger, T. D., Gooskens, S. L., van den Heuvel-Eibrink, M. M. & Pritchard-Jones, K. Biology and treatment of renal tumours in childhood. Eur. J. Cancer 68, 179–195 (2016).
pubmed: 27969569
doi: 10.1016/j.ejca.2016.09.005
pmcid: 27969569
Pritchard-Jones, K. et al. Treatment and outcome of Wilms’ tumour patients: an analysis of all cases registered in the UKW3 trial. Ann. Oncol. 23, 2457–2463 (2012).
pubmed: 22415585
doi: 10.1093/annonc/mds025
pmcid: 22415585
Rivera, M. N. & Haber, D. A. Wilms’ tumour: connecting tumorigenesis and organ development in the kidney. Nat. Rev. Cancer 5, 699–712 (2005).
pubmed: 16110318
doi: 10.1038/nrc1696
pmcid: 16110318
Maiti, S., Alam, R., Amos, C. I. & Huff, V. Frequent association of β-catenin and WT1 mutations in Wilms tumors. Cancer Res. 60, 6288–6292 (2000).
pubmed: 11103785
Ruteshouser, E. C., Robinson, S. M. & Huff, V. Wilms tumor genetics: mutations in WT1, WTX, and CTNNB1 account for only about one‐third of tumors. Genes, Chromosomes Cancer 47, 461–470 (2008).
pubmed: 18311776
pmcid: 4332772
doi: 10.1002/gcc.20553
Walz, A. L. et al. Recurrent DGCR8, DROSHA, and SIX homeodomain mutations in favorable histology Wilms tumors. Cancer Cell 27, 286–297 (2015).
pubmed: 25670082
pmcid: 4800737
doi: 10.1016/j.ccell.2015.01.003
Wegert, J. et al. Mutations in the SIX1/2 pathway and the DROSHA/DGCR8 miRNA microprocessor complex underlie high-risk blastemal type Wilms tumors. Cancer Cell 27, 298–311 (2015).
pubmed: 25670083
doi: 10.1016/j.ccell.2015.01.002
Hawthorn, L. & Cowell, J. K. Analysis of wilms tumors using SNP mapping array-based comparative genomic hybridization. PLoS One 6, e18941 (2011).
pubmed: 21544195
pmcid: 3081321
doi: 10.1371/journal.pone.0018941
Mengelbier, L. H. et al. Deletions of 16q in Wilms tumors localize to blastemal-anaplastic cells and are associated with reduced expression of the IRXB renal tubulogenesis gene cluster. Am. J. Pathol. 177, 2609–2621 (2010).
pubmed: 20847289
pmcid: 2966816
doi: 10.2353/ajpath.2010.100130
Hing, S. et al. Gain of 1q is associated with adverse outcome in favorable histology Wilms’ tumors. Am. J. Pathol. 158, 393–398 (2001).
pubmed: 11159177
pmcid: 1850292
doi: 10.1016/S0002-9440(10)63982-X
Gadd, S. et al. A Children’s Oncology Group and TARGET initiative exploring the genetic landscape of Wilms tumor. Nat. Genet. 49, 1487–1494 (2017).
pubmed: 28825729
pmcid: 5712232
doi: 10.1038/ng.3940
Jackson, E. M. et al. Genomic analysis using high-density single nucleotide polymorphism-based oligonucleotide arrays and multiplex ligation-dependent probe amplification provides a comprehensive analysis of INI1/SMARCB1 in malignant rhabdoid tumors. Clin. Cancer Res. 15, 1923–1930 (2009).
pubmed: 19276269
pmcid: 2668138
doi: 10.1158/1078-0432.CCR-08-2091
Song, H. C. et al. Biological characteristics of pediatric renal cell carcinoma associated with Xp11. 2 translocations/TFE3 gene fusions. J. Pediatr. Surg. 49, 539–542 (2014).
pubmed: 24726108
doi: 10.1016/j.jpedsurg.2013.10.005
Royer-Pokora, B. Genetics of pediatric renal tumors. Pediatr. Nephrol. 28, 13–23 (2013).
pubmed: 22461142
doi: 10.1007/s00467-012-2146-4
pmcid: 22461142
Drost, J. & Clevers, H. Organoids in cancer research. Nat. Rev. Cancer https://doi.org/10.1038/s41568-018-0007-6 (2018).
doi: 10.1038/s41568-018-0007-6
pubmed: 29692415
Sato, T. et al. Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche. Nature 459, 262–265 (2009).
pubmed: 19329995
doi: 10.1038/nature07935
Sato, T. et al. Long-term expansion of epithelial organoids from human colon, adenoma, adenocarcinoma, and Barrett’s epithelium. Gastroenterology 141, 1762–1772 (2011).
pubmed: 21889923
doi: 10.1053/j.gastro.2011.07.050
Gao, D. et al. Organoid cultures derived from patients with advanced prostate cancer. Cell 159, 176–187 (2014).
pubmed: 25201530
pmcid: 4237931
doi: 10.1016/j.cell.2014.08.016
Boj, S. F. et al. Organoid models of human and mouse ductal pancreatic cancer. Cell 160, 324–338 (2015).
pubmed: 25557080
doi: 10.1016/j.cell.2014.12.021
Huang, L. et al. Ductal pancreatic cancer modeling and drug screening using human pluripotent stem cell- and patient-derived tumor organoids. Nat. Med. 21, 1364–1371 (2015).
pubmed: 26501191
pmcid: 4753163
doi: 10.1038/nm.3973
Broutier, L. et al. Human primary liver cancer-derived organoid cultures for disease modeling and drug screening. Nat. Med. https://doi.org/10.1038/nm.4438 (2017).
doi: 10.1038/nm.4438
pubmed: 29131160
pmcid: 5722201
Nanki, K. et al. Divergent routes toward Wnt and R-spondin niche independency during human gastric carcinogenesis. Cell 174, 856–869 e817 (2018).
pubmed: 30096312
doi: 10.1016/j.cell.2018.07.027
Yan, H. H. N. et al. A comprehensive human gastric cancer organoid biobank captures tumor subtype heterogeneity and enables therapeutic screening. Cell Stem Cell https://doi.org/10.1016/j.stem.2018.09.016 (2018).
doi: 10.1016/j.stem.2018.09.016
pubmed: 30388424
pmcid: 6224657
Sachs, N. et al. A living biobank of breast cancer organoids captures disease heterogeneity. Cell https://doi.org/10.1016/j.cell.2017.11.010 (2017).
doi: 10.1016/j.cell.2017.11.010
pubmed: 29224780
Schutte, M. et al. Molecular dissection of colorectal cancer in pre-clinical models identifies biomarkers predicting sensitivity to EGFR inhibitors. Nat. Commun. 8, 14262, https://doi.org/10.1038/ncomms14262 (2017).
doi: 10.1038/ncomms14262
pubmed: 28186126
pmcid: 5309787
Pauli, C. et al. Personalized in vitro and in vivo cancer models to guide precision medicine. Cancer Discov. 7, 462–477 (2017).
pubmed: 28331002
pmcid: 5413423
doi: 10.1158/2159-8290.CD-16-1154
van de Wetering, M. et al. Prospective derivation of a living organoid biobank of colorectal cancer patients. Cell 161, 933–945 (2015).
pubmed: 25957691
pmcid: 6428276
doi: 10.1016/j.cell.2015.03.053
Fujii, M. et al. A colorectal tumor organoid library demonstrates progressive loss of niche factor requirements during tumorigenesis. Cell Stem Cell 18, 827–838 (2016).
pubmed: 27212702
doi: 10.1016/j.stem.2016.04.003
pmcid: 27212702
Vlachogiannis, G. et al. Patient-derived organoids model treatment response of metastatic gastrointestinal cancers. Science 359, 920–926 (2018).
pubmed: 29472484
pmcid: 6112415
doi: 10.1126/science.aao2774
Schutgens, F. et al. Tubuloids derived from human adult kidney and urine for personalized disease modeling. Nat. Biotechnol. 37, 303 (2019).
pubmed: 30833775
doi: 10.1038/s41587-019-0048-8
pmcid: 30833775
Watanabe, K. et al. A ROCK inhibitor permits survival of dissociated human embryonic stem cells. Nat. Biotechnol. 25, 681 (2007).
pubmed: 17529971
doi: 10.1038/nbt1310
pmcid: 17529971
Scott, J. et al. Insulin-like growth factor-II gene expression in Wilms’ tumour and embryonic tissues. Nature 317, 260–262 (1985).
pubmed: 2995818
doi: 10.1038/317260a0
pmcid: 2995818
Sehic, D., Ciornei, C. D. & Gisselsson, D. Evaluation of CITED1, SIX1, and CD56 protein expression for identification of blastemal elements in Wilms tumor. Am. J. Clin. Pathol. 141, 828–833 (2014).
pubmed: 24838327
doi: 10.1309/AJCPQ8Q0YTHSYZTX
Dekkers, J. F. et al. High-resolution 3D imaging of fixed and cleared organoids. Nat. Protoc. 14, 1756–1771 (2019).
pubmed: 31053799
doi: 10.1038/s41596-019-0160-8
Sigauke, E. et al. Absence of expression of SMARCB1/INI1 in malignant rhabdoid tumors of the central nervous system, kidneys and soft tissue: an immunohistochemical study with implications for diagnosis. Mod. Pathol. 19, 717–725 (2006).
pubmed: 16528370
doi: 10.1038/modpathol.3800581
Judkins, A. R., Mauger, J., Ht, A., Rorke, L. B. & Biegel, J. A. Immunohistochemical analysis of hSNF5/INI1 in pediatric CNS neoplasms. Am. J. Surg. Pathol. 28, 644–650 (2004).
pubmed: 15105654
doi: 10.1097/00000478-200405000-00013
Natrajan, R. et al. Array CGH profiling of favourable histology Wilms tumours reveals novel gains and losses associated with relapse. J. Pathol. 210, 49–58 (2006).
pubmed: 16823893
doi: 10.1002/path.2021
Young, E. E., Brown, C. T., Merguerian, P. A. & Akhavan, A. Pediatric and adolescent renal cell carcinoma. Urol. Oncol. 34, 42–49 (2016).
pubmed: 26299882
doi: 10.1016/j.urolonc.2015.06.009
Grobner, S. N. et al. The landscape of genomic alterations across childhood cancers. Nature 555, 321–327 (2018).
pubmed: 29489754
doi: 10.1038/nature25480
Alexandrov, L. B. et al. Signatures of mutational processes in human cancer. Nature 500, 415–421 (2013).
pubmed: 23945592
pmcid: 3776390
doi: 10.1038/nature12477
Alexandrov, L. B., Nik-Zainal, S., Wedge, D. C., Campbell, P. J. & Stratton, M. R. Deciphering signatures of mutational processes operative in human cancer. Cell Rep. 3, 246–259 (2013).
pubmed: 23318258
pmcid: 23318258
doi: 10.1016/j.celrep.2012.12.008
Ma, X. et al. Pan-cancer genome and transcriptome analyses of 1,699 paediatric leukaemias and solid tumours. Nature 555, 371–376 (2018).
pubmed: 29489755
pmcid: 29489755
doi: 10.1038/nature25795
Alexandrov, L. B. et al. The repertoire of mutational signatures in human cancer. Nature 578, 94–101 (2020).
Gadd, S. et al. Clinically relevant subsets identified by gene expression patterns support a revised ontogenic model of Wilms tumor: a Children’s Oncology Group Study. Neoplasia 14, 742–756 (2012).
pubmed: 22952427
pmcid: 3431181
doi: 10.1593/neo.12714
Joshi, V. V., Banerjee, A. K., Yadav, K. & Pathak, I. C. Cystic partially differentiated nephroblastoma: a clinicopathologic entity in the spectrum of infantile renal neoplasia. Cancer 40, 789–795 (1977).
pubmed: 196744
doi: 10.1002/1097-0142(197708)40:2<789::AID-CNCR2820400229>3.0.CO;2-R
Slade, I. et al. DICER1 syndrome: clarifying the diagnosis, clinical features and management implications of a pleiotropic tumour predisposition syndrome. J. Med. Genet. 48, 273–278 (2011).
pubmed: 21266384
doi: 10.1136/jmg.2010.083790
Wu, M. K. et al. Biallelic DICER1 mutations occur in Wilms tumours. J. Pathol. 230, 154–164 (2013).
pubmed: 23620094
doi: 10.1002/path.4196
Doros, L. A. et al. DICER1 mutations in childhood cystic nephroma and its relationship to DICER1-renal sarcoma. Mod. Pathol. 27, 1267–1280 (2014).
pubmed: 24481001
pmcid: 4117822
doi: 10.1038/modpathol.2013.242
Dome, J. S. et al. High telomerase RNA expression level is an adverse prognostic factor for favorable-histology Wilms’ tumor. J. Clin. Oncol. 23, 9138–9145 (2005).
pubmed: 16172460
doi: 10.1200/JCO.2005.00.562
Wegert, J. et al. Characterization of primary Wilms tumor cultures as an in vitro model. Genes, Chromosomes Cancer 51, 92–104 (2012).
pubmed: 22034155
doi: 10.1002/gcc.20936
Malouf, G. G. et al. Genomic heterogeneity of translocation renal cell carcinoma. Clin. Cancer Res. 19, 4673–4684 (2013).
pubmed: 23817689
doi: 10.1158/1078-0432.CCR-12-3825
Chun, H. E. et al. Identification and analyses of extra-cranial and cranial rhabdoid tumor molecular subgroups reveal tumors with cytotoxic T cell infiltration. Cell Rep. 29, 2338–2354 e2337 (2019).
pubmed: 31708418
pmcid: 6905433
doi: 10.1016/j.celrep.2019.10.013
Roerink, S. F. et al. Intra-tumour diversification in colorectal cancer at the single-cell level. Nature 556, 457–462 (2018).
pubmed: 29643510
doi: 10.1038/s41586-018-0024-3
Bardeesy, N. et al. Anaplastic Wilms’ tumour, a subtype displaying poor prognosis, harbours p53 gene mutations. Nat. Genet. 7, 91–97 (1994).
pubmed: 8075648
doi: 10.1038/ng0594-91
pmcid: 8075648
Ooms, A. H. et al. Significance of TP53 mutation in Wilms tumors with diffuse anaplasia: a report from the Children’s Oncology Group. Clin. Cancer Res. 22, 5582–5591 (2016).
pubmed: 27702824
pmcid: 5290091
doi: 10.1158/1078-0432.CCR-16-0985
Wegert, J. et al. TP53 alterations in Wilms tumour represent progression events with strong intratumour heterogeneity that are closely linked but not limited to anaplasia. J. Pathol. Clin. Res. 3, 234–248 (2017).
pubmed: 29085664
pmcid: 5653929
doi: 10.1002/cjp2.77
Drost, J. et al. Sequential cancer mutations in cultured human intestinal stem cells. Nature 521, 43–47 (2015).
pubmed: 25924068
doi: 10.1038/nature14415
pmcid: 25924068
Cresswell, G. D. et al. Intra-tumor genetic heterogeneity in Wilms tumor: clonal evolution and clinical implications. eBioMedicine 9, 120–129 (2016).
pubmed: 27333041
pmcid: 4972528
doi: 10.1016/j.ebiom.2016.05.029
Karlsson, J. et al. Four evolutionary trajectories underlie genetic intratumoral variation in childhood cancer. Nat. Genet. 50, 944–950 (2018).
pubmed: 29867221
doi: 10.1038/s41588-018-0131-y
pmcid: 29867221
Weeber, F. et al. Preserved genetic diversity in organoids cultured from biopsies of human colorectal cancer metastases. Proc. Natl Acad. Sci. USA 112, 13308–13311 (2015).
pubmed: 26460009
doi: 10.1073/pnas.1516689112
Kopper, O. et al. An organoid platform for ovarian cancer captures intra- and interpatient heterogeneity. Nat. Med. 25, 838–849 (2019).
pubmed: 31011202
doi: 10.1038/s41591-019-0422-6
Ohlund, D. et al. Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer. J. Exp. Med. 214, 579–596 (2017).
pubmed: 28232471
pmcid: 5339682
doi: 10.1084/jem.20162024
Seino, T. et al. Human Pancreatic tumor organoids reveal loss of stem cell niche factor dependence during disease progression. Cell Stem Cell https://doi.org/10.1016/j.stem.2017.12.009 (2018).
doi: 10.1016/j.stem.2017.12.009
pubmed: 29337182
Dijkstra, K. K. et al. Generation of tumor-reactive T cells by co-culture of peripheral blood lymphocytes and tumor organoids. Cell 174, 1586–1598 e1512 (2018).
pubmed: 6558289
pmcid: 6558289
doi: 10.1016/j.cell.2018.07.009
Drost, J. et al. Organoid culture systems for prostate epithelial and cancer tissue. Nat. Protoc. 11, 347–358 (2016).
pubmed: 26797458
pmcid: 4793718
doi: 10.1038/nprot.2016.006
Li, H. & Durbin, R. Fast and accurate long-read alignment with Burrows-Wheeler transform. Bioinformatics 26, 589–595 (2010).
pubmed: 2828108
pmcid: 2828108
doi: 10.1093/bioinformatics/btp698
Blokzijl, F. et al. Tissue-specific mutation accumulation in human adult stem cells during life. Nature 538, 260–264 (2016).
pubmed: 27698416
pmcid: 5536223
doi: 10.1038/nature19768
DePristo, M. A. et al. A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nat. Genet. 43, 491–498 (2011).
pubmed: 3083463
pmcid: 3083463
doi: 10.1038/ng.806
Boeva, V. et al. Control-FREEC: a tool for assessing copy number and allelic content using next-generation sequencing data. Bioinformatics 28, 423–425 (2012).
pubmed: 22155870
doi: 10.1093/bioinformatics/btr670
Nilsen, G. et al. Copynumber: efficient algorithms for single- and multi-track copy number segmentation. BMC Genomics 13, 591 (2012).
pubmed: 23442169
pmcid: 3582591
doi: 10.1186/1471-2164-13-591
Blokzijl, F., Janssen, R., van Boxtel, R. & Cuppen, E. MutationalPatterns: comprehensive genome-wide analysis of mutational processes. Genome Med. 10, 33 (2018).
pubmed: 29695279
pmcid: 5922316
doi: 10.1186/s13073-018-0539-0
Johann, P. D. et al. Atypical teratoid/rhabdoid tumors are comprised of three epigenetic subgroups with distinct enhancer landscapes. Cancer Cell 29, 379–393 (2016).
pubmed: 26923874
doi: 10.1016/j.ccell.2016.02.001
Muraro, M. J. et al. A single-cell transcriptome atlas of the human pancreas. Cell Syst. 3, 385–394 e383 (2016).
pubmed: 5092539
pmcid: 5092539
doi: 10.1016/j.cels.2016.09.002
Candelli, T. et al. Sharq, A versatile preprocessing and QC pipeline for Single Cell RNA-seq. BioRxiv, 2018.
Butler, A., Hoffman, P., Smibert, P., Papalexi, E. & Satija, R. Integrating single-cell transcriptomic data across different conditions, technologies, and species. Nat. Biotechnol. 36, 411–420 (2018).
pubmed: 29608179
pmcid: 6700744
doi: 10.1038/nbt.4096
Kowalczyk, M. S. et al. Single-cell RNA-seq reveals changes in cell cycle and differentiation programs upon aging of hematopoietic stem cells. Genome Res. 25, 1860–1872 (2015).
pubmed: 26430063
pmcid: 4665007
doi: 10.1101/gr.192237.115
Lun, A. T., McCarthy, D. J. & Marioni, J. C. A step-by-step workflow for low-level analysis of single-cell RNA-seq data with Bioconductor. F1000Res 5, 2122 (2016).
pubmed: 27909575
pmcid: 5112579
Yu, G., Wang, L. G., Han, Y. & He, Q. Y. clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS 16, 284–287 (2012).
pubmed: 22455463
pmcid: 3339379
doi: 10.1089/omi.2011.0118
Aran, D. et al. Reference-based analysis of lung single-cell sequencing reveals a transitional profibrotic macrophage. Nat. Immunol. 20, 163–172 (2019).
pubmed: 30643263
pmcid: 6340744
doi: 10.1038/s41590-018-0276-y